A bivalent compound targeting CCR5 and the mu opioid receptor treats inflammatory arthritis pain in mice without inducing pharmacologic tolerance

A bivalent compound targeting CCR5 and the mu opioid receptor treats inflammatory arthritis pain in mice without inducing pharmacologic tolerance

Abstract Background Pain accompanies rheumatoid arthritis and other chronic inflammatory conditions and is difficult to manage. Although opioids provide potent analgesia, chronic opioid use can cause tolerance and addiction. Recent studies have demonstrated functional interactions between chemokine...

Full description

Bibliographic Details
Main Authors: Raini Dutta, Mary M. Lunzer, Jennifer L. Auger, Eyup Akgün, Philip S. Portoghese, Bryce A. Binstadt
Format: Article
Language:English
Published: BMC 2018-07-01
Series:Arthritis Research & Therapy
Subjects:
Analgesia
CCR5
Chemokine receptor
Heteromer
Inflammation
Opioid receptor
Online Access:http://link.springer.com/article/10.1186/s13075-018-1661-5

Internet

http://link.springer.com/article/10.1186/s13075-018-1661-5

Similar Items